Astrup AS, Nielsen FS, Rossing P, Ali S, Kastrup J, Smidt UM, Parving HH.（2007）Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens. 25, 2479– 2485.
Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, Dixon DL.（2017）Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 6, e005686.
Bouhanick B, Bongard V, Amar J, Bousquel S, Chamontin B. （ 2008 ） Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. Diabetes Metab. 34, 560–567.
Buda VA, Ciobanu DM, Roman G.（2018）Pulse pressure is more relevant than systolic and diastolic blood pressure in patients with type 2 diabetes and cardiovascular disease. Clujul Medical.91, 408-413.
Cherney D, Perkins BA, Soleymanolou N, Har R, Fagan N, Johansen OE, Woerle HJ, Eynatten M, Broedl UC.（2014）The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovascular Diabetology 13, 28
Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE. （ 2015 ） Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 17, 1180-1193.
Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE.（2017）Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension. Diabetes, Obesity and Metabolism 19, 1620-1624.
Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H.（2019）Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. Diabetes, Obesity and Metabolism 21, 710-714.
Colosia AD, Palencia R, Khan S.（2013）Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 6, 327‐338.
DeFronzo RA, Norton L, Abdul-Ghani M.（2017）Renal, metabolic, and cardiovascular considerations of SGLT2 inhibition. Nephrology 13, 11-26.
Ferdinand KC, Izzo JL, Lee J, Meng L, George J, Salsali A, Seman L（. 2019）Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension. Circulation 139, 2098-2109
Friedewald WT, Levy RI, Fredrickson DS. （ 1972 ） Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18, 499–502.
Fujii T, Uzu T, Nishimura M, Takeji M, Kuroda S, Nakamura S, Inenaga S, Kimura G.（1999） Circadian rhythm of natriuresis is disturbed in non dipper type of essential hypertension. American Journal of Kidney Disease 33, 29-35.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, et al, TECOS Study Group.（2015）Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 373, 232-42.
Gueguen C, Burke SL, Barzel B, Eikelis N, Watson AMD, Jha JC, Jackson KL, Sata Y, Lim K, Lambertet GW, al.（2020）Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes. Diabetologia 63, 1424-1434.
Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. （ 2011 ）Predictive Role of the Nighttime Blood Pressure. Hypertension 57, 3-10.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, et al.; DAPA-CKD Trial Committees and Investigators（: 2020）. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 383, 1436-1446.
Hermida RC, E Ayala, H Smolensky, Fernández JR, Mojón A, Portaluppi F.
（2017）Sleep-time blood pressure: Unique sensitive prognostic marker of vascular risk and therapeutic target for prevention. Sleep Medicine Reviews 33, 17-27
Hu R, McDonough AA, Layton AT.（2021）Sex differences in solute and water handling in the human kidney: Modeling and functional implications. iScience 24, 102667
Kario K, Ferdinand KC, O'Keefe JH. （ 2020 ） Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Progress of Cardiovascular Diseases 63, 249-262.
Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, Uchiyama K, Niijima Y, Katsuya T, Urata H, et al.（ 2018） 24-Hour Blood Pressure- Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study. Circulation 139, 2089-2097.
Kinguchi S, Wakui H, Ito Y, Kondo Y, Azushima K, Osada U, Yamakawa T, Iwamoto T, Yutoh J, Misumi T, et al.（2019）Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study（Y-AIDA study）. Cardiovascular Diabetology 18, 110.
Kumarathurai P, Anholm C, Larsen BS, Olsen RH, Madsbad S, Kristiansen O, Nielsen OW, Haugaard SB, Sajadieh A.（2017）Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care 40, 117-124.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration.（ 2002） Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913.
Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JF, et al. Action to Control Cardiovascular Risk in Diabetes Study Group.（2008）Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 358, 2545- 2559.
Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, et al. Collaborators on the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation（SPIKE）Trial.（2016）Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima- Media Thickness Evaluation（SPIKE）: A Randomized Controlled Trial. Diabetes Care 39: 455-64
Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, Myers MG, Ogedegbe G, Schwartz JE, Townsend RR, et al. （ 2019 ） Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension 73, e35-e66 N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, S Kaptoge, E Di Angelantonio, E Ingelsson, D A Lawlor, E Selvin, M Stampfer, C D A Stehouwer, et al. （ 2010 ） Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375, 2215-22.
Nakano S, Uchida K, Kigoshi T, Azukizawa S, Iwasaki R, Kaneko M, Morimoto S.（1991）Circadian rhythm of blood pressure in normotensive NIDDM subjects. Its relationship to microvascular complications. Diabetes Care 14, 707-711
Neal B, Perkovic V, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group.（2017）. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 377, 644-57
Newman JC, Verdin E.（ 2014） Ketone bodies as signaling metabolites. Trends Endocrinol Metab. 25, 42-52.
Okada K, Iso H, Cui R, Inoue M, Tsugane S.（2011）Pulse pressure is an independent risk factor for stroke among middle-aged Japanese with normal systolic blood pressure: the JPHC study. Journal of Hypertension 29, 319-324.
Osorio H, Bautista R, Rios A, Franco M, Arellano A,Vargas-Robles H, Romo E, Escalante B.（ 2010） Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats. J Nephrol. 23, 541-546.
Palatini P, Reboldi G, Beilin LJ, Casiglia E,Eguchi E,Imai Y,Kario K,Ohkubo T, Pierdomenico SD, Schwartz JE, Wing L, Verdecchia P.（2017） Masked tachycardia. A predictor of adverse outcome in hypertension. Journal of Hypertension 35, 487-492.
Paul L, Hastie CE, Li WS, Harrow C, Muir S, Connell JMC, Dominiczak AF, McInnes GT, Padmanabhan S（. 2010）Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 55, 567- 574.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, et al.; CREDENCE Trial Investigators（: 2019）Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 380, 2295-306.
Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz-Runge S, Kaastrup P,Hvelplund A, Bardram L, Calatayud D, Knudsen LB（. 2014）GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280-90.
Qiong W, Changchang L, Yanfang G, Barnett AG, Tong S, Phung D, Chu C, Dear K, Wang X, Huang C.（2016）Environmental ambient temperature and blood pressure in adults: A systematic review and meta-analysis. Sci Total Environ. 575, 276-286.
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, et al. CARMELINA Investigators. （ 2019 ） Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 321, 69-79.
Sabolic I, Vrhovac I, Eror DV, Gerasimova M, Rose M, Breljak D, Ljubojevic M, Brzica H, Sebastiani A, Thal SC, et al.（2012）Expression of Na+-D- glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol. 302, C1174-88
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. SAVOR-TIMI 53 Steering Committee and Investigators. （ 2013 ） Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 369, 1317-1326.
Shirabe S, Maeda H, Koike Y, et al. （ 2017 ） Analysis of the effect of luseogliflozin on patients with type 2 diabetes and hypertension using ambulatory blood pressure monitoring. Journal of the Japan Diabetes Society 60, S354.
Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ, EMPA-REG BP Investigators. （ 2015 ） Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension. Diabetes Care 38, 420-428
Vinik A, Maser RE, Mitchell BD, Freeman R.（2003）Diabetic Autonomic Neuropathy. Diabetes care 26, 1553-79
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators（2016）Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med.375, 323-334.
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al.（2013）the EXAMINE Investigators: Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med.369, 1327-1335
Zhang X, Zhao Q（. 2016）Effect of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type2 diabetes: A systematic review and meta- analysis. Journal of Hypertension 34;167-175
Zheng J, Sun Z, Guo X, Xie Y, Sun Y, Zheng L.（2019）Blood pressure predictors of stroke in rural Chinese dwellers with hypertension: a large- scale prospective cohort study. BMC Cardiovascular Disorder 19, 206.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. EMPA-REGOUTCOME Investigators（. 2015）Empagliflozin, Cardiovascular Outcomes,and Mortality in Type 2 Diabetes. N Engl J Med. 26, 2117-28
日本循環器学会，日本高血圧学会，日本心臓病学会合同班. （2010）. 24 時間血圧計の使用（ ABPM ） 基準に関するガイドライン（ 2010 年改訂版） Guidelines for the clinical use of 24 hour ambulatory blood pressure monitoring（ABPM）（JCS 2010）
日本糖尿病学会、SGLT2 阻害薬の適正使用に関する委員会.（2014）SGLT2阻害薬の適正使用に関する Recommendation
論文の公開元へ
